ID   SUM149R
AC   CVCL_C9AM
SY   SUM-149PT(R)
DR   BioGRID_ORCS_Cell_line; 1395
DR   Wikidata; Q123033571
RX   PubMed=26735014;
RX   PubMed=32416067;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Selected for resistance to: ChEBI; CHEBI:137113; JQ1.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (from parent cell line).
CC   Omics: CRISPR phenotypic screen.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4001; Breast inflammatory carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3422 ! SUM149PT
SX   Female
AG   40Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=26735014; DOI=10.1038/nature16508;
RA   Shu S.-K., Lin C.Y., He H.-S.H., Witwicki R.M., Tabassum D.P.,
RA   Roberts J.M., Janiszewska M., Huh S.J., Liang Y., Ryan J., Doherty E.,
RA   Mohammed H., Guo H., Stover D.G., Ekram M.B., Brown J., D'Santos C.,
RA   Krop I.E., Dillon D., McKeown M.R., Ott C., Qi J., Ni M., Rao P.K.,
RA   Duarte M., Wu S.-Y., Chiang C.-M., Anders L., Young R.A., Winer E.,
RA   Letai A.G., Barry W.T., Carroll J.S., Long H., Brown M.A., Liu X.-L.S.,
RA   Meyer C.A., Bradner J.E., Polyak K.;
RT   "Response and resistance to BET bromodomain inhibitors in
RT   triple-negative breast cancer.";
RL   Nature 529:413-417(2016).
//
RX   PubMed=32416067; DOI=10.1016/j.molcel.2020.04.027;
RA   Shu S.-K., Wu H.-J., Ge J.Y., Zeid R., Harris I.S., Jovanovic B.,
RA   Murphy K., Wang B.-B., Qiu X.-T., Endress J.E., Reyes J., Lim K.,
RA   Font-Tello A., Syamala S., Xiao T.-F., Reddy Chilamakuri C.S.,
RA   Papachristou E.K., D'Santos C., Anand J., Hinohara K., Li W.,
RA   McDonald T.O., Luoma A., Modiste R.J., Nguyen Q.-D., Michel B.,
RA   Cejas P., Kadoch C., Jaffe J.D., Wucherpfennig K.W., Qi J., Liu X.-L.S.,
RA   Long H., Brown M.A., Carroll J.S., Brugge J.S., Bradner J.E., Michor F.,
RA   Polyak K.;
RT   "Synthetic lethal and resistance interactions with BET bromodomain
RT   inhibitors in triple-negative breast cancer.";
RL   Mol. Cell 78:1096-1113.e8(2020).
//